{
    "clinical_study": {
        "@rank": "161477", 
        "arm_group": [
            {
                "arm_group_label": "Aerobic Training during Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Aerobic Training (AT) will be prescribed based on the guiding American College of Sports Medicine principles with the aim of improving VO2peak. The AT intervention will work toward the target of 3 treadmill walking sessions/week at 60%-85% of baseline VO2peak for 150 mins.wk-1 Walking was chosen because it is the preferred mode of exercise training for BC patients."
            }, 
            {
                "arm_group_label": "Aerobic Training after Therapy", 
                "arm_group_type": "Experimental", 
                "description": "Aerobic Training will be prescribed based on the guiding ASCM principles with the aim of improving VO2peak after the completion of chemotherapy. The AT intervention will work toward the target of 3 treadmill walking sessions/week at 60%-85% of baseline VO2peak for 150 mins.wk-1 Walking was chosen because it is the preferred mode of exercise training for BC patients."
            }, 
            {
                "arm_group_label": "Continuous Aerobic Training", 
                "arm_group_type": "Experimental", 
                "description": "This group will follow the identical aerobic training during and after therapy prescription as described for Groups 1 and 2 for the first 24 weeks (i.e., during therapy). After primary therapy (i.e., at ~24 weeks, T1), the AT prescription will be re-prescribed based on the end of therapy VO2peak assessment (at T1) with the goal of 3 exercise sessions per week, for 30-45 mins/session at 60% to 85% of VO2peak."
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Experimental", 
                "description": "This group will get educational information and be eligible for exercise after completion of all study-related assessments."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a four-arm randomized trial to compare the effects of supervised aerobic\n      training (AT) performed during, after, or during and after (i.e., continuous AT) standard\n      primary adjuvant therapy, relative to control in early-stage breast cancer (BC) patients.\n      The study team will recruit a total of 160 sedentary women with histologically confirmed\n      early-stage BC scheduled to initiate standard adjuvant primary therapy."
        }, 
        "brief_title": "Aerobic Training During or After Adjuvant Therapy", 
        "completion_date": {
            "#text": "August 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. sedentary (i.e., <150 min.wk-1 of moderate intensity over the past month, as per ASCM\n             guidelines8),\n\n          2. willingness to travel to Duke University Medical Center  as necessitated by\n             facility-based intervention sessions, and\n\n          3. medical clearance from attending oncologist.\n\n        Exclusion Criteria:\n\n          1. Presence of metastatic disease, and\n\n          2. subjects must not have any absolute contraindications to exercise testing for cancer\n             patients as recommended by our group (e.g., acute myocardial infarction, room air\n             desaturation at rest \u226485%).The investigators have specifically selected subgroup of\n             patients who will all receive chemotherapy and radiation therapy to directly address\n             the question of safety and impact during therapy. Subjects must not have any of\n             following absolute contraindications to maximal exercise testing as recommended by\n             the American Thoracic Society and exercise testing guidelines for cancer patients:\n\n               1. acute myocardial infarction (3-5 days),\n\n               2. unstable angina,\n\n               3. uncontrolled arrhythmias causing symptoms or hemodynamic compromise,\n\n               4. syncope,\n\n               5. acute endocarditis,\n\n               6. acute myocarditis or pericarditis,\n\n               7. uncontrolled heart failure,\n\n               8. acute pulmonary embolus or pulmonary infarction,\n\n               9. thrombosis of lower extremities,\n\n              10. suspected dissecting aneurysm,\n\n              11. uncontrolled asthma,\n\n              12. pulmonary edema,\n\n              13. room air desaturation at rest \u226485%,\n\n              14. respiratory failure,\n\n              15. acute noncardiopulmonary disorder that may affect exercise performance or be\n                  aggravated by exercise,\n\n              16. mental impairment leading to inability to cooperate, and\n\n              17. extensive bone metastases.\n\n          3. pregnancy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943695", 
            "org_study_id": "Pro00036284"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aerobic Training during Therapy", 
                    "Aerobic Training after Therapy", 
                    "Continuous Aerobic Training"
                ], 
                "intervention_name": "Aerobic Therapy", 
                "intervention_type": "Behavioral", 
                "other_name": "exercise, breast cancer, therapy."
            }, 
            {
                "arm_group_label": "Control", 
                "description": "Subjects will be given material regarding cancer and it's impact.", 
                "intervention_name": "Educational Information", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast Cancer", 
            "Exercise", 
            "Chemotherapy"
        ], 
        "lastchanged_date": "October 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Aerobic Training During or After Adjuvant Therapy: A Randomized Control Trial", 
        "overall_official": {
            "affiliation": "DUMC", 
            "last_name": "Lee W Jones, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To determine the optimal timing of aerobic activity, relative to an attention-control group, on exercise capacity in a breast cancer setting. This will be measured via treadmill walking 3 days per week at the Duke Center for Living.", 
            "measure": "Change in VO2 peak (functional capacity)", 
            "safety_issue": "Yes", 
            "time_frame": "during chemotherapy 3-6 months depending on treatment recommendations"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943695"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.", 
                "measure": "Quality of Life measured by questionnaire during and after Chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
            }, 
            {
                "description": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.", 
                "measure": "Sleeping patterns as measured by questionnaire during and after Chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
            }, 
            {
                "description": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.", 
                "measure": "Depression scale during and after Chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
            }, 
            {
                "description": "Determine the effects on patient-reported outcomes. Time frame can vary based on individual length of chemotherapy.", 
                "measure": "Physical activity recall during and after Chemotherapy", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
            }, 
            {
                "description": "To examine the physiological mediators of the exercise training - exercise capacity relationship (e.g., skeletal muscle function as assessed by a muscle biopsy)performed at the Duke Aesthetics Building.", 
                "measure": "Skeletal Muscle Function", 
                "safety_issue": "Yes", 
                "time_frame": "at baseline, mid-point (12 weeks approximately) , and follow-up (24 weeks approximately) testing"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Duke University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}